BRIEF REPORT
Lakshmi Karra, MD, MS; Allison Costello, MD, MBA; Brooke M. Trudeau, PharmD; Morteza Khodaee, MD, MPH
Corresponding Author: Morteza Khodaee, MD, MPH; University of Colorado School of Medicine - Department of Family Medicine.
Email: Morteza.khodaee@cuanschutz.eduDOI: 10.3122/jabfm.2022.220285R1Keywords: Immunization, Measles-Mumps-Rubella Vaccine, Public HealthDates: Submitted: 08-23-2022; Revised: 10-11-2022; Accepted: 10-13-2022
Ahead of Print: | HTML | | PDF | Final Publication: | HTML | | PDF |
The Centers for Disease Control (CDC) recommend two documented doses of the MMR (measles-mumps-rubella) vaccine for adequate measles, mumps, and rubella immunity for all children and most adults. Sometimes, individuals are asked to provide serological proof of immunity to measles, mumps, and/or rubella for educational or employment purposes. In other instances, serological testing may be used to help clarify whether an individual has immunity to measles, mumps, and/or rubella. These serological tests may sometimes show negative or equivocal antibody titers to measles, mumps and/or rubella, raising the question of adequate immunity. This report provides practical guidance for clinicians on when to use serologic testing to determine measles, mumps, and rubella immunity.